eplerenone售价多少呢？

It is a new highly selective aldosterone receptor blocker that can be used for the treatment of heart failure, hypertension, and coronary heart disease. With the continuous progress of research, the scope of clinical application of eplerenone is constantly being expanded, and its status in the field of cardiovascular disease treatment is also constantly improving.

How much does eplerenone cost? 

Eplerenone was developed by Pfizer of the United States and first launched in the United States in 2002. It is mainly used clinically to treat hypertension. In 2003, it was approved by the FDA for the treatment of heart failure after acute myocardial infarction. Eplerenone is not currently on the market in my country, so we have no way of knowing the domestic price. Medical Travel learned that in 2019, the price of eplerenone 25mg-30 tablets/box in the United States was around US$118.71. However, the price of eplerenone 50mg*100 tablets from India's Lupine Pharmaceuticals is around RMB 500, which is very cheap. Patients can purchase it through Medical Companion Travel.

Subgroup analysis of the EPHESUS study also showed that the effect of eplerenone on reducing overall mortality was more obvious in patients with hypertension. A comparative study on the efficacy and tolerability of 499 patients with grade 1 or 2 hypertension who were randomized to receive enalapril or eplerenone showed that at 6 months, enalapril was as effective as eplerenone in reducing systolic blood pressure (eplerenone reduced 14.5 mmHg; enalapril reduced 12.7 mmHg: P=0.199) and diastolic blood pressure (eplerenone reduced 11.2 mmHg; enalapril reduced 11.3 mm Hg; P=0.910). After 12 months, the two groups were also similar (eplerenone-16.5/-13.3mmHg; enalapril-14.8/-14.1mmHg, P values ​​0.251 and 0.331 respectively). The rates of withdrawal due to adverse events (7.9% for eplerenone and 9.3% for enalapril at 6 months) and treatment failure were also equal (23.3% for eplerenone and 22.8% for enalapril at 6 months). About 2/3 of the patients in each group achieved normal blood pressure at 6 months with the above single treatment. In the eplerenone group, the reduction in blood pressure was independent of renin levels, unlike enalapril. Both groups can reduce proteinuria above normal levels, but the eplerenone group is more obvious (-61.5% vs -25.7%; P=0.01); eplerenone can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%), and clinical trials have proven that it can also be used for heart failure after acute myocardial infarction and congestive heart failure after acute myocardial infarction.